A randomized double blind placebo controlled multicenter study published in Journal of Clinical Hypertension Greenwich Conn. evaluated the antihypertensive efficacy and safety of azilsartan medoxomil AZL M compared with placebo and olmesartan medoxomil OLM M . Researchers determined the change from baseline in mean 24 hour ambulatory systolic blood pressure SBP following 6 weeks of treatment. Overall 1275 patients with primary hypertension and baseline 24 hour mean ambulatory systolic pressure 8805 130 mmHg and 8804 170 mmHg were studied 142 patients were administered placebo while the remainder were given 20 mg 40 mg or 80 mg AZL M or 40 mg OLM M. Baseline mean 24 hour SBP was 146 mmHg. Dose dependent reductions in 24 hour mean SBP were noted in all AZL M groups at study end. Reduction in 24 hour mean SBP was greater with AZL M 80 mg than OLM M 40 mg by 2.1 mmHg AZL M 40 mg was noninferior to OLM M 40 mg. AZL M thus appeared to be well tolerated and more efficacious at its maximal dose as compared to the highest dose of OLM M.